Previous Article | Next Article ![]()
Journal of Clinical Microbiology, December 1999, p. 4179-4182, Vol. 37, No. 12
Department of Biomedical Research,
Received 26 March 1999/Returned for modification 4 June
1999/Accepted 9 September 1999
A dipstick assay for the detection of brucella-specific
immunoglobulin M antibodies was evaluated with 707 sera from 247 laboratory-confirmed brucellosis patients and 342 control sera from
brucellosis-free individuals. These sera were collected from six
different countries. The assay was found to be highly sensitive and
specific. In addition, the test is easy to use and does not require
specialized training or equipment, and the components are stable
without a requirement for refrigeration. All of these factors make the
test ideal for developing countries and rural settings.
Brucellosis is an important but
often neglected cause of morbidity in many regions of the world
(1, 2, 4, 9, 17, 19, 25). The disease is most common in
rural areas and among those involved in animal husbandry. Brucellosis
also occurs in urban settings when animals are kept in compounds around
houses and among meat-packers, dairy workers, and veterinarians.
Brucella abortus, Brucella suis, and
Brucella melitensis are the causative agents, which have,
respectively, cattle, swine, and goats and sheep as their main hosts.
The disease is transmitted from infected animals by direct contact with
blood, fetuses and fetal membranes, uterine secretions, and aborted
material or through consumption of infected, raw animal products, of
which milk and milk products are the most important (26).
The treatment of chronic brucellosis is complicated and requires
prolonged medication compared to that for acute brucellosis; the
disease should be diagnosed and treated promptly. Typical severe acute
brucellosis in its early stages cannot be diagnosed on clinical grounds
along (11). Symptoms and signs are nonspecific, and several
other febrile illnesses may be simulated, as for example glandular
fever, influenza, malaria, and enteric infections. Also, when an
unusual complication is present, brucellosis may be overlooked. Laboratory tests such as culture and serological tests including the
serum agglutination test (SAT) (7, 24), the anti-human globulin test (Coombs test) (21), the complement fixation
test (12), and enzyme-linked immunosorbent assay (ELISA)
(5, 13, 20), therefore, are indispensable for an accurate diagnosis.
The detection of Brucella-specific immunoglobulin M (IgM)
antibodies allows the diagnosis of patients with brucellosis at an
early stage or acute disease and also may help to discriminate between
patients in the early phase of brucellosis and those with chronic
brucellosis. In countries where the disease is highly endemic, a large
proportion of the population may have persistent Brucella-specific IgG antibodies. Under such conditions, the
detection of specific IgM antibodies is important to make the
laboratory diagnosis of brucellosis in the early phase of the disease.
Specific IgM antibodies can be detected by SAT performed in the
presence of either 2-mercaptoethanol (2-ME test) or dithiothreitol
(SAT-DTT) (3, 10, 18, 22) and by ELISA (5, 13,
20). The SATs and ELISA can be performed only by relatively
skilled personnel in well-equipped laboratories, and these tests are
too elaborate for widespread application under field conditions. In
situations where appropriate diagnostic facilities are lacking, a
colorimetric test, with a simplified format, giving a positive or
negative result could serve as a confirmatory test for human
brucellosis in the acute phase of the disease. For this reason, we
developed a simple dipstick assay for the detection of
Brucella-specific IgM antibodies in human serum samples,
which is evaluated in this paper.
The dipstick heat-resistant antigen was prepared from a liquid culture
of B. abortus 1119-2 by heating washed cells at 95°C followed by removal of cell debris by centrifugation, and this preparation was then applied as a distinct line to a nitrocellulose strip (16). To obtain an internal control, an anti-human IgM antibody was applied as a coating to the nitrocellulose as a separate line (16). The coated strips were blocked with skimmed milk and dried, made to adhere to a plastic backing with double-sided tape,
cut into 2.5-mm-wide sticks, and shipped with a vial of wetting agent.
A nonenzymatic detection reagent was prepared by conjugation of a
monoclonal anti-human IgM antibody to colloidal dye particles (palanyl
red) according to a patented method (14, 15, 23). To
increase stability, the stained antibody suspension was lyophilized and
shipped with a rehydration reagent in a separate bottle
(16). The dipstick assay is performed by incubation for 3 h of a wetted dipstick in 250 µl of reconstituted detection reagent mixed with 5 µl of a serum sample. At the end of the
incubation period, the dipstick is thoroughly rinsed with tap water in
order to remove excess detection reagent and air dried at ambient
temperature. A reddish-stained antigen band indicates a positive
reaction. The staining of the antigen band can be scored as 1+ through
4+ by comparison with a colored reference strip; when no coloring is
observed, the test is negative. In order to assess the clinical utility
of the assay, laboratories in Portugal, Russia, Spain, The Netherlands,
and the United States were provided with dipsticks, test reagents, and
test tubes and were asked to perform the assay according to an
accompanying protocol. In the laboratories in Portugal, Russia, Spain,
and The Netherlands, randomly selected serum samples from
laboratory-confirmed brucellosis patients and brucellosis-free
individuals were tested in order to determine the sensitivity and
specificity of the assay at different stages of the disease and the
results of these studies were combined. Furthermore, samples from an
outbreak of brucellosis were tested in the United States, and in Yemen,
a group of samples from culture-proven patients was tested.
The first study group of 150 patients included 39 patients with 71 samples from Portugal, 90 patients from Russia, 19 patients with 49 samples from Spain, and 2 patients from The Netherlands. Patients were
considered laboratory-confirmed brucellosis patients based on the
results of culture, SAT, and Coombs test. Thirty-nine (26%) patients
had positive blood cultures, 38 of which were positive for B. melitensis and 1 of which was positive for B. suis. The control group (342 samples) included 94 patients with clinical suspicion of brucellosis but negative results in the Rose Bengal test.
The remaining members of the control group were patients with the
following conditions (number of patients): autoimmune disease (28),
bartonellosis (Bartonella henselae) (2), hantavirus infection (11), hepatitis A (5), hepatitis B (7), human
immunodeficiency virus infection (20), legionellosis (11),
leptospirosis (8), Lyme borreliosis (20), malaria (20), meningitis (7),
meningococcal meningitis (8), Mycoplasma pneumoniae
infection (7), ochrobacteriosis (2), syphilis (20), toxoplasmosis (9),
tularemia (Francisella tularensis) (12), Yersinia
pseudotuberculosis II infection (1), Yersinia
enterocolitica 03 infection (1), and Y. enterocolitica 09 infection (4). Forty-five serum samples from
healthy donors were also included.
To calculate the sensitivity of the dipstick assay at different stages
of brucellosis, the serum samples from the patients were stratified
according to the duration of the disease: 73 samples collected within 2 months, 77 samples for the period of 2 to 4 months, 52 samples for the
period of 4 to 6 months and 77 samples collected after >6 months of
treatment (Table 1). The sensitivity of
the dipstick assay was 89.0% for the samples collected within 2 months
after the onset of the disease and 83.1% for the samples collected 2 to 4 months after the onset of the disease (Table 2). The sensitivity dropped to 32.6 and
29.8% for the two groups of samples collected after 4 and 6 months of
treatment, respectively (Table 2). Furthermore, the staining intensity
of the antigen band of the dipstick was moderate (2+) to strong (4+)
for most of the positive samples collected early in the disease (Table 1). The percentages of the four groups that stained as >1+ declined with the duration of treatment: 82.2, 58.4, 17.3, and 10.3%,
respectively (Table 1). Compared with that of the SAT, the sensitivity
of the dipstick assay was higher for the samples collected during the
first 4 months of the disease but lower for the samples collected after
the fourth month (Table 2). The sensitivity of the dipstick assay for
the samples collected during the first 4 months also was higher than or
equal to that of the Coombs test (Table 2). The sensitivity of the
dipstick assay was higher than the sensitivity of the SAT performed in
the presence of reducing agent, an assay often used to assess the
presence of specific IgM antibodies, for all four groups of samples.
The difference in sensitivity between these two assays was largest for
the samples collected 2 to 4 months after the onset of the disease.
Samples collected from 5 of 89 patients during the first 6 months of
the disease were negative in the dipstick assay. These samples were
also negative in the 2-ME test. The clinical symptoms of these five
patients were consistent with chronic brucellosis rather than acute or recent-onset brucellosis; the final diagnosis was Brucella
arthritis, spondylitis, and neurobrucellosis for one patient each, and
Brucella was isolated from bone marrow from two patients.
Only 4 of 297 samples from the noncase patients gave a positive result
in the dipstick assay, giving a specificity of 98.6%. These four
patients included one suspected brucellosis patient with a negative
result in the Rose Bengal test, one patient with syphilis, and two
patients with yersiniosis. The staining intensity of all four samples
was rated 2+. None of the 45 blood bank sera gave a positive result.
Of the case patients from Portugal, Russia, and Spain, 39 patients had
a positive blood culture. Serum samples from 36 (92.3%) of these 39 blood culture-positive patients gave a positive result in the dipstick
assay. Of the patients with a positive result in the dipstick assay,
one was culture positive for B. suis and the others were
positive for B. melitensis. To demonstrate the reactivity of
the dipstick for patients infected with B. abortus, a group
of single serum samples from 60 culture-proven patients from Yemen was
tested. Of these patients, 42 had a positive culture for B. abortus and 18 were positive for B. melitensis. The
sensitivity of the dipstick assay for these two groups of patients was
95.2 and 83.3%, respectively. The majority (53 and 80%, respectively) of the dipstick-positive samples of these two groups gave a moderate to
strong staining intensity.
To validate the dipstick assay further and to test the reactivity of
the dipstick assay for patients with a B. suis infection, the assay was applied on 93 paired serum samples derived from 37 laboratory-confirmed brucellosis patients infected with B. suis during a localized outbreak in a slaughterhouse in the United States during 1976. All initial serum samples tested positive in the
dipstick, giving a sensitivity of 100% (Table
3). Of the samples taken 12 months on
average after the first sample, 61% still tested positive, but while
the staining intensity of the initial samples was
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Development and Evaluation of a Rapid Dipstick
Assay for Serodiagnosis of Acute Human Brucellosis
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
TABLE 1.
Staining intensity of dipstick assay for samples
collected at different stages of the disease
TABLE 2.
Sensitivity of dipstick assay and other serological tests
in relation to duration of the disease
2+ for all but one
sample, most of the subsequent samples gave a 1+ staining intensity.
TABLE 3.
Dipstick results and sensitivity for serum samples
collected from brucellosis patients during a B. suis
slaughterhouse outbreak in the United States (1976)
The results of the present study show that the dipstick assay is highly sensitive and specific for the serodiagnosis of human brucellosis in the early phase of the disease. For the combined group of samples from Portugal, Russia, Spain, and The Netherlands, the sensitivity was 89.0% for samples collected during the first 2 months of the disease and 83.1% for samples collected 2 to 4 months after the onset of the disease. The sensitivity for the group of samples from the United States collected early in the disease during an outbreak of brucellosis was even higher (100%). Infection with B. melitensis was the most common cause of disease among the first study group. All patients in the outbreak were infected with B. suis. The somewhat lower sensitivity of the dipstick assay calculated for the results of the first study, however, most likely was not related to the difference in causative agent. Some of the patients with a negative result in the dipstick assay from the first study group likely suffered from chronic disease despite the reported recent onset of the disease, and this may well have accounted for the lower sensitivity. The dipstick assay performed equally well for the confirmation of suspected brucellosis patients with B. abortus, B. melitensis, or B. suis infections. The sensitivity was high irrespective of whether it was calculated based on the results obtained for patients confirmed by serological methods or by culture. The sensitivity was 93.5% when only blood culture-proven brucellosis patients were considered.
The specificity of the dipstick assay was calculated to be 98.6%. The selectivity for sera of patients with Y. enterocolitica or cholera infection needs further investigation, as these organisms share antigenic structures with brucellas (6, 8). However, the symptoms of patients with yersiniosis or cholera are distinct from those of patients with brucellosis.
The high sensitivity and specificity of the dipstick assay for samples
collected in the acute phase of the disease demonstrated that the assay
is highly suitable for use in serodiagnosis of patients with acute
disease. Compared with SAT-DTT or the 2-ME test, the dipstick assay has
a higher sensitivity and is easier to use: the dipstick assay requires
only a few minutes of handling time to perform, does not need special
equipment or electricity, and can be performed by modestly trained
personnel with a minimum of instructions. The dipstick assay also is
easier to apply than ELISA. The dipstick assay is suited for use in the
field and in laboratories that are not equipped to perform the more
complicated tests. The assay also has potential to replace the other
methods for distinguishing patients with acute brucellosis from those with a chronic infection or with persisting IgG antibodies due to a
previous infection. It may be noted, though, that consistent with the
results of ELISA (7, 11) our results show that specific IgM
antibodies may remain detectable for several months and sometimes even
much longer after the onset of the disease. However, while most serum
samples collected early in the disease gave a
2+ staining, most of
the sera collected later, 4 to 6 months after treatment had been
initiated, tested as 1+.
The five laboratories participating in the study found the test easy to perform and were satisfied with the result. It was also noted that the development of color on the dipstick could be maintained as a permanent record in a folder or attached to the patient record.
In conclusion, the dipstick assay described here is an easy-to-perform method for the quick serodiagnosis of acute human brucellosis. Due to its robustness and simplicity, the assay is highly suitable for application under field conditions. Ideally, application of two dipsticks, one for the detection of specific IgM antibodies and another for the detection of specific IgG antibodies, would be needed to cover the possibility of both acute or recent and chronic brucellosis. The development of an IgG-specific rapid test for brucellosis is now in progress. A further prospective study will be required to demonstrate the clinical utility of the assay and to calculate the sensitivity, specificity, and predictive value for patients living in an area where brucellosis is endemic.
| |
ACKNOWLEDGMENTS |
|---|
We acknowledge J. Bongers and R. Weijts for gifts of sera. The secretarial assistance of I. Struiksma is highly appreciated.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Biomedical Research, Royal Tropical Institute, Meibergdreef 39, 1105 AZ Amsterdam, The Netherlands. Phone: 31-20-5665470. Fax: 31-20-6971841. E-mail: H.Smits{at}kit.nl.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Abo-Shehada, M.,
J. S. Odeh,
M. Abu-Essud, and N. Abuharfeil.
1996.
Seroprevalence of brucellosis among high risk people in Northern Jordan.
Int. J. Epidemiol.
25:450-454 |
| 2. | Al-Eissa, Y., F. Al-Zamil, M. Al-Mugeiren, S. Al-Rasheed, A. Al-Sanie, and A. Al-Mazyad. 1991. Childhood brucellosis: a deceptive infectious disease. Scand. J. Infect. Dis. 23:129-133[Medline]. |
| 3. |
Anderson, R. K.,
R. Jenness,
H. P. Brumfield, and P. Gough.
1964.
Brucella-agglutinating antibodies: relation of mercaptoethanol stability to complement fixation.
Science
143:1334-1335 |
| 4. | Araj, G. F., and R. A. Azzam. 1996. Seroprevalence of brucella antibodies among persons in high-risk occupation in Lebanon. Epidemiol. Infect. 117:281-288[Medline]. |
| 5. | Ariza, J., T. Pellicer, R. Pallarés, and F. Gudiol. 1992. Specific antibody profile in human brucellosis. Clin. Infect. Dis. 14:131-140[Medline]. |
| 6. | Avhonen, P., and K. Sievers. 1969. Yersinia enterocolitica infection associated with Brucella agglutinins. Clinical feature of 24 patients. Acta Med. Scand. 185:121-125[Medline]. |
| 7. | Buchanan, T. M., C. R. Sulzer, M. K. Frix, and R. A. Feldman. 1974. Brucellosis in the United States, 1960-1972. An abattoir-associated disease. Medicine 53:415-425[Medline]. |
| 8. | Dajani, Y. F., A. Aziz Masoud, and H. F. Barakat. 1989. Epidemiology and diagnosis of human brucellosis in Jordan. J. Trop. Med. Hyg. 92:209-214[Medline]. |
| 9. | Díaz, R., E. Maraví-Poma, S. Fernádez, S. García-Merlo, and A. A. Rivero-Puento. 1982. Brucellosis: estudio de 222 casos. Parte IV: diagnóstico de la brucellosis humana. Rev. Clin. Esp. 166:107-110[Medline]. |
| 10. | Díaz, R., I. Moriyón, C. Gamazo, B. Alonso-Urmeneta, and M. de la Vinda. 1991. Laboratory diagnosis of human brucellosis, p. 93-107. In M. Plommet (ed.), Prevention and control of brucellosis in the Mediterranean countries. [Pudoc Scientific Publishersi, Wageningen, The Netherlands. |
| 11. | Caroff, M., M. B. Bundle, J. W. Perry, J. W. Cherwonogrodzky, and J. R. Duncan. 1984. Antigen S-type lipopolysaccharide of Brucella abortus 1119-3. Infect. Immun. 46:383-388. |
| 12. | Foz, A., and L. Arcalis. 1953. Die Komplementbindungs-Reaktion in der diagnosis der menschlichen brucellosis. Z. Hyg. 136:55-66. |
| 13. | Gazapo, E., J. Gonzales Lahoz, J. L. Subiza, M. Baquera, J. Gil, and E. G. de la Concha. 1989. Changes in IgM and IgG antibody concentrations in brucellosis over time: importance for diagnosis and follow-up. J. Infect. Dis. 159:219-225[Medline]. |
| 14. | Gribnau, T., F. Roeles, J. van der Biezen, J. Leuvering, and A. Schuurs. 1982. The application of colloidal dye particles as label in immunoassays: disperse(d) dye immunoassay ("DIA"), p. 411-424. In T. C. J. Gribnau, J. Visser, and R. J. F. Nivard (ed.), Affinity chromatography and related techniques. Elsevier, Amsterdam, The Netherlands. |
| 15. | Gribnau, T., A. van Someren, and F. van Dinther. 1983. DIA-disperse dye immunoassay, p. 275-280. In I. M. Chaiken, M. Wilchek, and I. Parikh (ed.), Affinity chromatography and biological recognition. Academic Press, Inc., Orlando, Fla. |
| 16. | Gussenhoven, G. C., M. A. W. G. van der Hoorn, M. G. A. Goris, W. J. Terpstra, R. A. Hartskeerl, B. W. Mol, C. W. van Ingen, and H. L. Smits. 1997. LEPTO Dipstick, a dipstick assay for the detection of Leptospira-specific immunoglobulin M antibodies in human sera. J. Clin. Microbiol. 35:92-97[Abstract]. |
| 17. | Idris, M. A., M. Maiwald, K. N. El-Mauly, and A. Ruppel. 1993. Human brucellosis in Dhofar, Sultanate of Oman. J. Trop. Med. Hyg. 96:46-50[Medline]. |
| 18. |
Kerr, W. R.,
W. J. Mccaughey,
J. D. Coghlan,
D. J. H. Payne,
R. A. Quaife,
L. Robertson, and D. Farrell.
1968.
Techniques and interpretation in the serodiagnosis of brucellosis in man.
J. Med. Microbiol.
1:181-193 |
| 19. |
Kiel, F. W., and M. Y. Khan.
1987.
Analysis of 506 consecutive positive serological tests.
J. Clin. Microbiol.
25:1384-1387 |
| 20. | Lulu, A. R., M. Y. Mustafa, and M. I. Khateeb. 1986. Evaluation of ELISA in the diagnosis of acute and chronic brucellosis in human beings. J. Hyg. 97:457-469. |
| 21. |
Otero, J. R.,
A. Fuertes,
E. Palenque, and A. R. Noriega.
1982.
Microtiter-adapted method that facilitates the Coombs test for brucellosis.
J. Clin. Microbiol.
16:737-738 |
| 22. | Reddin, L., R. K. Anderson, R. Jenness, and W. W. Spink. 1965. Significance of 7S and macroglobulin brucella agglutinins in human brucellosis. N. Engl. J. Med. 272:1263-1268. |
| 23. | Snowden, K., and M. Hommel. 1991. Antigen detection immunoassay using dipsticks and colloidal dyes. J. Immunol. Methods 140:57-65[Medline]. |
| 24. | Spink, W. W., N. B. McCullough, L. M. Hutchings, and C. K. Mingle. 1954. A standardized antigen and agglutination technique for human brucellosis. Am. J. Clin. Pathol. 24:496-498[Medline]. |
| 25. | Veerman, J., M. A. Basahi, and M. Al Qadasi. 1995. Human brucellosis. An old enemy or a new threat? Practitioner (East Mediterr. Ed.) 15:687-689. |
| 26. | Young, E. J. 1994. An overview of human brucellosis. Clin. Infect. Dis. 21:283-290. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»